| Zacks Company Profile for FibroGen, Inc (FGEN : NSDQ) |
|
|
| |
| • Company Description |
| FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.
Number of Employees: 225 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $7.35 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 69,082 shares |
| Shares Outstanding: 4.04 (millions) |
| Market Capitalization: $29.71 (millions) |
| Beta: 0.74 |
| 52 Week High: $38.25 |
| 52 Week Low: $4.85 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-4.70% |
-8.27% |
| 12 Week |
2.69% |
-13.62% |
| Year To Date |
-44.48% |
-48.00% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
350 Bay Street Suite 100 #6009
-
SAN FRANCISCO,CA 94158
USA |
ph: 415-978-1200
fax: 415-978-1902 |
ir@fibrogen.com |
http://www.fibrogen.com |
|
|
| |
| • General Corporate Information |
Officers
Thane Wettig - Chief Executive Officer
James A. Schoeneck - Chairman of the Board and Director
David DeLucia - Senior Vice President and Chief Financial Officer
Aoife Brennan - Director
Jeffrey L. Edwards - Director
|
|
Peer Information
FibroGen, Inc (GSAC)
FibroGen, Inc (CASI)
FibroGen, Inc (ALCD.)
FibroGen, Inc (OMNN)
FibroGen, Inc (CGPI.)
FibroGen, Inc (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 31572Q881
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
|
|
Share - Related Items
Shares Outstanding: 4.04
Most Recent Split Date: 6.00 (0.04:1)
Beta: 0.74
Market Capitalization: $29.71 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-2.38 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-17.38 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/25 |
|
|
|
| |
